Condition: Atopic Dermatitis · Sponsor: Johann E Gudjonsson MD PhD
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
This description comes directly from the study's public registry record.
Diane Fiolek · 734-763-1469 · dianemch@med.umich.edu
Always discuss trial participation with your own doctor first.
| Physioseq USA - CA | Folsom, California, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| University of Freiburg | Freiburg im Breisgau, Germany | Not Yet Recruiting |
| Lausanne University Hospital | Lausanne, Switzerland | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06906497